#victoza injection pen | Explore Tumblr posts and blogs

ozempic-pens · 1 year ago

Text

Exploring The Benefits & Usage Of The Victoza Injection Pen

The Victoza injection pen is a cutting-edge medical device designed to provide effective treatment for individuals dealing with type 2 diabetes. This blog post aims to provide comprehensive information about the Victoza injection pen, its benefits, & how it is used to manage diabetes. If you or a loved one are considering Victoza as a treatment option, read on to discover more.

Understanding Victoza Injection Pen: The Victoza injection pen is a portable device that delivers the medication liraglutide. It belongs to a class of drugs called GLP-1 receptor agonists, which help regulate blood sugar levels by increasing insulin secretion and reducing glucose production by the liver.

Benefits of Victoza Injection Pen:

Effective Blood Sugar Control: Victoza helps lower blood sugar levels and reduces the risk of complications associated with diabetes. Weight Management: Many patients experience weight loss while using Victoza, making it beneficial for those struggling with obesity. Cardiovascular Protection: Studies have shown that Victoza may provide cardiovascular benefits by reducing the risk of heart-related issues.

How to Use the Victoza Injection Pen: a. Preparation: Gather the pen, medication, alcohol swab, and a new needle. Make sure the medication is at room temperature. b. Cleaning: Clean the injection site with an alcohol swab and let it dry. c. Loading the Pen: Attach a new needle, remove the cap, and prime the pen as per the manufacturer’s instructions. d. Injection: Inject the medication into the cleaned area as demonstrated by your healthcare provider. e. Disposal: Safely dispose of the needle and pen in a sharps container.

Dosage and Administration: The dosage of Victoza varies and should be determined by your healthcare provider. Typically, it is injected once daily at any time, with or without food.

Conclusion: The Victoza injection pen offers a convenient & effective way to manage type 2 diabetes. Its numerous benefits, ease of use, and potential for weight loss make it a valuable treatment option. However, it’s crucial to work closely with your healthcare provider to determine if Victoza is suitable for your individual needs.

#victoza injection pen #victoza injection #victoza injection for diabetes #victoza liraglutide injection #victoza pen injector

0 notes

12percentspider · 8 months ago

Text

Hi! I'm currently looking into this scam and how it may be connected with one or more other scams, and I have some interesting insight on the images being used! I was re-investigating a twitter account I at the time suspected was connected to a now-defunct cancer scam as well as a periodically ongoing insulin scam and was led to this post by searching the name associated with the paypal-hosted fundraiser the twitter account is using.

These scammers do NOT know how diabetes works, be it type 1 or 2, and this is actually further proof of that.

The text is a little small, but the "insulin" pictured is not even actually insulin, it's another medication that happens to come in an injection pen that looks a lot like an insulin pen. I recognized it because while I'm type 1, I have multiple relatives who are type 2 and one used to use it. Being that said relative has tried to offer me their medications when I was low- claiming it's the same when it's NOT- I decided to look it up. Victoza, which is what's pictured, is not for use by t1d patients. So yes, further proof these scammers are counting on people not knowing anything about diabetes or insulin.

scammers are scum of the earth in a time where every dollar counts, so just make sure to block @/esth-care, @/ann-qm as well as any donation link that leads to anah qussim.

#oh boy i should probably note that somewhere now that i have the info post oof #further scam info

282 notes · View notes

utahtrimclinic · 2 years ago

Text

GLP-1 weight loss program

Many people struggle to reduce weight. Even when they follow a balanced diet and exercise routine; as a result, some people may seek alternative means of weight loss, such as medicine.

Weight loss might vary based on the GLP-1 medicine used and the dosage. According to research, utilising liraglutide can result in a weight loss of 10.5 to 15.8 pounds (4.8 to 7.2 kilogrammes, or kg). According to studies, those who used semaglutide and made lifestyle adjustments lost roughly 33.7 pounds (15.3 kilograms) compared to 5.7 pounds (2.6 kilograms) in those who did not take medicine in weight loss glp 1.

What are the Types of the GLP-1 Weight loss program?

GLP-1 receptor agonists are either short-acting (given once or twice a day) or long-acting (administered once a week). Insurance coverage, medical history, cost (purchase GLP-1 receptor agonists), personal preference, and blood sugar control efficacy all influence the kind recommended. There are a total of 7 discovered GLP-1 Weight loss programs till now; they are:

GLP-1 weight loss program includes:

Wegovy (injectable semaglutide) is taken once weekly.

Monaro (injectable terzepatide) is taken once weekly.

Ozempic (injectable semaglutide) taken once weekly

Rebels (oral semaglutide) taken daily as a pill

Trulicity (injectable dulaglutide) taken once weekly

Saxenda (injectable liraglutide) taken once weekly

Victoza (injectable liraglutide) is taken once weekly

Wegovy

Semaglutide is the active ingredient in Wegovy. It belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. Segovia has yet to be available in generic form.

Segovia is available as a liquid solution in a single-dose pen. Segovia will be injected beneath the skin by you.

This prescription medication is used with exercise and a low-calorie diet for long-term weight loss in individuals with a BMI of 27 or higher (overweight) and a weight-related health condition.

Monaro

Monaro is an injectable prescription medicine intended to improve blood sugar (glucose) levels in people with type 2 diabetes mellitus in conjunction with diet and exercise.

It is unknown if Mounjaro can be utilised in patients who have suffered pancreatic inflammation (pancreatitis). Those with type 1 diabetes should avoid using Mounjaro. Monaro is not proven to be safe or effective in children under the age of 18.

Ozempic

Ozempic, a diabetic treatment, had lately attracted notice when celebrities, a tech entrepreneur, and TikTok influencers recounted using it to reduce weight quickly.

The FDA originally authorised the injectable pharmaceutical for treating diabetes in 2017. In 2021, the FDA approved Wegovy, a drug with a greater dosage of the main component in Ozempic, called semaglutide, to treat obesity.

Rebels

Rebels (semaglutide) is an oral diabetic medication to enhance blood sugar management in persons over 18. It is frequently provided after oral diabetic treatments have failed or have ceased functioning.

Rebels should be taken on an empty stomach, at least 30 minutes before eating, and with a modest amount of water (no more than 4 oz). This ensures that Rybelsus is adequately absorbed. You may eat, drink, or take other oral medications after 30 minutes of taking the Rybelsus pill.

Rebels are not prescribed for the treatment of type 1 diabetes.

Trulicity

Trulicity is an injectable diabetic medication that aids in blood sugar management.

Trulicity is used in individuals with type 2 diabetes mellitus, together with diet and exercise, to enhance blood sugar management.

Trulicity also treats persons with type 2 diabetes and heart disease and minimises their risk of significant cardiac issues such as heart attack or stroke.

Trulicity is not utilised in the treatment of type 1 diabetes.

Saxenda

Saxenda functions similarly to a hormone that occurs naturally in the body and aids in regulating blood sugar, insulin levels, and digestion.

Saxenda is an injectable prescription medication that may assist confident obese or overweight adults who also have weight-related medical issues, as well as children aged 12 to 17 years with a body weight of more than 132 pounds (60 kg) and obesity, lose weight and keep it off. It is taken in conjunction with diet and exercise.

Victoza

Victoza functions similarly to a hormone that exists naturally in the body and aids in regulating blood sugar, insulin levels, and digestion.

Victoza is used in adults and children ten years of age and older with type 2 diabetes mellitus, together with diet and exercise, to improve blood sugar management.

In individuals with type 2 diabetes and heart disease, Victoza may also help lower the risk of significant cardiac issues such as heart attack or stroke. It is frequently used when other diabetic medications have failed. Victoza is not approved for the treatment of type 1 diabetes.

0 notes

siglerprescriptiondrugcards · 4 years ago

Text

Liraglutide (rDNA Origin)

Common Brand Name: Victoza, Saxenda*

Common Dosage Forms:

Solution for Injection (Victoza): Pre-filled, multi-dose 3 mL pens deliver doses of 0.6 mg, 1.2 mg, 1.8 mg (6 mg/mL).

*Saxenda is not covered on this card. Is indicated with diet and exercise for weight management in adults.

FDA Indications/Dosages:

As an adjunct to diet and exercise to improve glycemic control in adults: One dose administered once daily by subcutaneous injection in the abdomen, thigh, or upper arm and independent of meals. Starting dose is 0.6 mg daily for one week and is intended to reduce gastrointestinal adverse effects during titration. After one week at 0.6 mg daily, increase the daily dose to 1.2 mg. If 1.2 mg does not produce sufficient glycemic control, the daily dose may be increased to 1.8 mg. Consider reducing the dose of concomitantly given sulfonylureas during initial titration.

Monitor: FBG, HbA1c, serum calcitonin

Pharmacology/Pharmacokinetics: Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist (97% similar to human GLP-1). In the presence of glucose, liraglutide increases intracellular cyclic AMP which results in the release of insulin from pancreatic beta cells. This insulin release decreases as glucose levels decrease. Liraglutide also decreases glucagon secretion in a glucose-dependent manner and delays gastric emptying. Unlike human GLP-1 which has a half-life of about 2 minutes, liraglutide has a half-life of 13 hours. Peak concentrations are reached 8-12 hours post dose. Plasma protein binding is extensive (98%). Liraglutide is endogenously metabolized similar to other proteins.

Drug Interactions: May decrease the plasma levels of digoxin and lisinopril. Additive effects may be seen when given with sulfonylureas.

Contraindications/Precautions: CONTRAINDICATED IN PATIENTS WITH A PERSONAL OR FAMILY HISTORY OF MEDULLARY THYROID CARCINOMA and in patients with Multiple Endocrine Neoplasia syndrome type 2. LIRAGLUTIDE INCREASES THE RISK OF MEDULLARY THYROID CARCINOMA, pancreatitis, hypoglycemia, and renal impairment. Pregnancy Category C.

Adverse Effects: Most common adverse effects are gastrointestinal in nature and include nausea (28%), diarrhea (17%), vomiting (11%), and constipation (10%). May also cause headache (9%). Rare but serious adverse effects include medullary thyroid carcinoma, pancreatitis, and renal impairment.

Patient Consultation:

Promptly report any signs of thyroid carcinoma (mass in the neck, dysphagia, dyspnea, or persistent hoarseness).

Promptly report any symptoms of pancreatitis (persistent severe abdominal pain with or without vomiting).

If a dose is missed, skip it and return to once daily dosing. Do not double doses. If more than 3 days have lapsed between doses, reinitiate with 0.5 mg daily.

Read and understand the medication guide which comes with the medication.

Store unused pens in the refrigerator. Opened pens may be stored below 86°F (30°C) for 30 days. If exposed to temperatures over 86°F, it should be discarded.

Do not store with a needle attached. Use a new needle for each dose.

#sigler drug cards #36th edition #liraglutide #rdna origin #victoza #saxenda #antidiabetic #drug facts

0 notes

pharmaphorumuk · 4 years ago

Text

Price cut leads NICE to back Novo Nordisk’s obesity drug Saxenda

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management.

The cost-effectiveness agency for England and Wales has recommended Saxenda (liraglutide) as a treatment option for people with a body mass index (BMI) of 35 or more, and who are also pre-diabetic with a high risk of developing cardiovascular disease because of risk factors such as high blood pressure or high cholesterol levels.

NICE tuned down the GLP-1 agonist earlier this year, but changed its stance after Novo Nordisk offered a confidential discount to the NHS.

Saxenda – which comes as prefilled self-injection pen – will be used as part of a programme based on a reduced-calorie diet and increased physical activity, according to NICE, and treatment should be discontinued if patients don’t lose at least 5% of their body eight within 12 months.

“Our independent committee was presented with clinical evidence which showed that people lose more weight with liraglutide plus lifestyle measures than with lifestyle measures alone,” said Meindert Boysen, NICE’s deputy chief executive.

“Liraglutide may also delay the development of type 2 diabetes and cardiovascular disease and this is the main benefit of treatment,” he added. It will be prescribed in secondary care, by a specialist multidisciplinary tier 3 weight management service.

Denmark-based Novo Nordisk said there are 13 million obese people in England with obesity, placing them at risk not only of diabetes and heart disease but also severe COVID-19 symptoms if infected with SARS-CoV-2.

The NICE recommendation coincided with Novo Nordisk’s third quarter results statement, which showed modest 3% growth for Saxenda in the first nine months of the year to DKK 4.2 billion ($661 million), held back by the impact of the pandemic on patients accessing healthcare.

That also put a brake on Novo Nordisk’s other products, which are mainly use for chronic diseases like diabetes, although it said a “gradual recovery” occurred in the third quarter. All told, sales grew 7% in the nine months to just under DKK 95 billion ($14.9 billion).

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide.

The company’s GLP-1 agonists for diabetes grew strongly, thanks to its once-weekly injectable Ozempic (semaglutide) which grew 119% to DKK 15 billion ($2.35 billion), overtaking Novo Nordisk’s older Victoza (liraglutide) product which requires dosing by injection every day.

Ozempic is squaring off in the market against Eli Lilly’s Trulicity (dulaglutide), which grew 22% to $3.57 billion in the same period.

Novo Nordisk also recorded DKK 1 billion ($156 million) in sales for its new oral formulation of semaglutide – Rybelsus – which started to roll out this year.

The post Price cut leads NICE to back Novo Nordisk’s obesity drug Saxenda appeared first on .

from https://pharmaphorum.com/news/price-cut-leads-nice-to-back-novo-nordisks-obesity-drug-saxenda/

0 notes

freesuitwhispers · 4 years ago

Text

Global Diabetes Market Insights and Forecast to 2020-2025

Summary – A new market study, “ Global Diabetes Market Insights and Forecast to 2020-2025 ” has been featured on WiseGuyReports.

Global diabetes market is expected to grow at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 8.9%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate. Diabetic drugs are highly priced which could be one of the major drawbacks.

Diabetic devices includes blood glucose meters and insulin delivery devices. The market for blood glucose meters will have the highest market share compared to the insulin delivery systems such as syringes and injection pens. Continuous glucose monitoring systems will have the highest market growth. Meter and strips are expected to dominate the overall market share in diabetic devices.

Overall the market is driven by growing burden of diabetes on economies. U.S. alone spends 11% of its health expenditure on diabetes. India and China are most affected by diabetes with over 120 million patients. A majority of diabetes patients are either undiagnosed or lack the basic treatment. The impending unmet needs are forcing the companies and governments to provide basic needs for diabetes. Research and development is ongoing to development long term solution for diabetes. Some of the leading manufacturers are trying to develop artificial pancreas. Currently CGMS devices are being used with insulin pumps as secondary prototype for artificial pancreas. It is expected that artificial pancreas will be ready for commercialization by next decade. Development of artificial pancreas has gained support from USFDA, which is a major boost for the market.

Also Read : https://www.medgadget.com/2019/05/global-diabetes-market-segmentation-parameters-and-prospects-2019-to-2023-market-research-report.html

North America is the leading geography followed by Europe and Asia Pacific. Asia Pacific is expected to have the highest growth rate amongst the regions. North American market is driven by high awareness, availability of reimbursements and high expenditure on healthcare. Asia Pacific market is driven by high population of diabetic patients.

The report provides detailed & insightful chapters which include market overview, key findings, strategic recommendations, market estimations, patent analysis, pipeline analysis, market determinants, key company analysis, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Market segments included in the report:

Diabetes by Type

Type 1 Diabetes

Type 2 Diabetes

Gestational Diabetes

Drug Class

Alpha-Glucosidase Inhibitors

Amylin Analogs

Antidiabetic Combinations

Dipeptidyl Peptidase 4 Inhibitors

Incretin Mimetics

Insulin

Meglitinides

Non-Sulfonylureas

Sglt-2 Inhibitors

Sulfonylureas

Thiazolidinediones

Diabetic Devices

Blood Glucose Meters

Blood Glucose Strips

Insulin Injection Pens

Insulin Syringes

Continuous Glucose Monitoring Systems

Insulin Pumps

Lancets

THE REPORT COVERS:

Comprehensive research methodology of Diabetes market

In-depth analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global Diabetes market

Insights about market determinants which are stimulating the global Diabetes market

Detailed and extensive market segments with regional distribution of forecasted revenues

Extensive profiles and recent developments of market players

FOR MORE DETAILS : https://www.wiseguyreports.com/reports/3204442-global-diabetes-market-research-and-forecast-2018-2023

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 2035002763 (UK)

#Diabetes Market

0 notes

charlesphillips3813-blog · 5 years ago

Text

<a href="https://www.devonpharmacy.com/">Devon Blogspot</a>

<a href="https://www.devonpharmacy.com/product/buy-humalog-kwikpen-online-buy-humalog-buy-humalog-insulin/">buy humalog kwikpen online-buy humalog-buy humalog insulin</a>

<a href="https://www.devonpharmacy.com/product/buy-lantus-solostar-online-buy-lantus-solostar-pen-online/">buy lantus solostar online-buy lantus solostar pen online</a>

<a href="https://www.devonpharmacy.com/product/buy-novolog-flexpen-online-buy-novolog-insulin-online/">buy novolog flexpen online-buy novolog insulin online</a>

<a href="https://www.devonpharmacy.com/product/buy-ozempic-online-ozempic-buy-ozempic-medication-where-to-buy/">buy ozempic online-ozempic buy-ozempic medication where to buy</a>

<a href="https://www.devonpharmacy.com/product/buy-saxenda-usa-buy-saxenda-injections-buy-saxenda-uk/">buy saxenda usa-buy saxenda injections-buy saxenda UK</a>

<a href="https://www.devonpharmacy.com/product/buy-toujeo-across-the-border-where-to-buy-toujeo-solostar-pen-cheap/">buy toujeo across the border-where to buy toujeo solostar pen cheap</a>

<a href="https://www.devonpharmacy.com/product/buy-trulicity-online-can-i-buy-trulicity-from-canada-buy-trulicity-in-mexico/">buy trulicity online-can i buy trulicity from canada-buy trulicity in mexico</a>

<a href="https://www.devonpharmacy.com/product/where-to-buy-victoza-cheap-buying-victoza-online-buy-victoza-uk/">where to buy victoza cheap-buying victoza online-buy victoza uk</a>

<a href="https://www.devonpharmacy.com/product/qsymia-buy-online-buy-topiramate-uk-buy-qsymia-diet-pills-online/">qsymia buy online-buy topiramate uk-buy qsymia diet pills online</a>

<a href="https://www.devonpharmacy.com/product/buy-adipex-p-online-buy-adipex-p-buy-weight-loss-pills-online/">buy adipex p online-buy adipex-p-buy weight loss pills online</a>

<a href="https://www.devonpharmacy.com/product/buy-alli-120-capsules-online-where-to-buy-alli-diet-pills-cheap/">Buy Alli 120 Capsules Online</a>

<a href="https://www.devonpharmacy.com/product/buy-alli-84-capsules-online-where-can-i-buy-alli-diet-pills-australia/">Buy Alli 84 Capsules online -where can i buy alli diet pills Australia</a>

<a href="https://www.devonpharmacy.com/product/buy-belviq-online-lorcaserin-buy-online-buy-belviq-australia-buy-belviq/">buy belviq online-lorcaserin buy online-buy belviq Australia-buy belviq</a>

<a href="https://www.devonpharmacy.com/product/buy-contrave-online-buy-contrave-diet-pill-online-buy-contrave-online-uk/">buy contrave online-buy contrave diet pill online-buy contrave online UK</a>

<a href="https://www.devonpharmacy.com/product/jadera-plus-weight-loss-pills-jadera-weight-loss-pills-suppliers/">Jadera plus weight loss pills- jadera weight loss pills suppliers</a>

<a href="https://www.devonpharmacy.com/product/buy-jadera-slimming-max-best-weight-loss-pills-you-can-buy-in-stores/">Buy Jadera Slimming Max-best weight loss pills you can buy in stores</a>

<a href="https://www.devonpharmacy.com/product/jadera-weight-loss-supplement-buy-jadera-weight-loss-supplement/">Jadera Weight Loss Supplement-Buy Jadera Weight Loss Supplement</a>

<a href="https://www.devonpharmacy.com/product/meridia-diet-pills-buy-online-buy-sibutramine-online-buy-meridia-15mg/">meridia diet pills buy online-buy sibutramine online-buy meridia 15mg</a>

<a href="https://www.devonpharmacy.com/product/buy-orlistat-online-buy-xenical-online-buy-orlistat-buy-xenical/">buy orlistat online-buy xenical online-buy orlistat-buy xenical</a>

We are strong

In the way we are.

169 notes · View notes

ashleyisking · 8 years ago

Text

So yesterday was the first day of me shooting 1.2. I got super sick when I tried to eat some funnel fries. And assumed it was just because I didn't need them anyway and the meds were doing their job. But it lasted forever. I ended up skipping lunch because of it Then having to force my self to get something for dinner. Today is the second day and hopefully it goes better. I ate breakfast fine. I am worried because I may had messed up the injection this morning. I think I pulled the pen up to soon and a bubble formed under my skin. Has this happened to anyone else? How do you feel about victoza

#victoza #diabetic #type two diabetes

1 note · View note

nickyshukla1 · 4 years ago

Text

Global Diabetes Market - Global Demand, Sales, Consumption and Forecasts 2018-2023

Summary - A new market study, titled “ Global Diabetes Market - Global Demand, Sales, Consumption and Forecasts 2018-2023 ” has been featured on WiseGuyReports

ALSO READ: http://heraldkeeper.com/news/global-diabetes-market-covid-19-impact-on-industry-analysis-size-share-growth-trends-forecasts-2025-506063.html

Market segments included in the report:

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3204442-global-diabetes-market-research-and-forecast-2018-2023

About Us:

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK

#Diabetes Market

0 notes

ketan-wagh121-blog · 4 years ago

Text

DIABETES MARKET – GLOBAL INDUSTRY ANALYSIS, SIZE, SHARE, GROWTH, TRENDS AND FORECAST 2018 – 2023

Global Diabetes Industry

New Study On “2018-2023 Diabetes Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3204442-global-diabetes-market-research-and-forecast-2018-2023

Market segments included in the report:

Diabetes by Type Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Drug Class Alpha-Glucosidase Inhibitors Amylin Analogs Antidiabetic Combinations Dipeptidyl Peptidase 4 Inhibitors Incretin Mimetics Insulin Meglitinides Non-Sulfonylureas Sglt-2 Inhibitors Sulfonylureas Thiazolidinediones Diabetic Devices Blood Glucose Meters Blood Glucose Strips Insulin Injection Pens Insulin Syringes Continuous Glucose Monitoring Systems Insulin Pumps Lancets THE REPORT COVERS: Comprehensive research methodology of Diabetes market In-depth analysis of macro and micro factors influencing the market guided by key recommendations. Analysis of regional regulations and other government policies impacting the global Diabetes market Insights about market determinants which are stimulating the global Diabetes market Detailed and extensive market segments with regional distribution of forecasted revenues Extensive profiles and recent developments of market players

Also Read: https://www.abnewswire.com/pressreleases/diabetes-market-global-industry-analysis-size-share-growth-trends-and-forecast-2018-2023_257591.html

For more information or any query mail at [email protected]

About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us: Norah Trent +1 646 845 9349 / +44 208 133 9349 Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

0 notes

healthcarebiz · 7 years ago

Text

Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

LISBON, Portugal, Sept. 13, 2017 /PRNewswire/ --

Oral Presentation 113

In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.[1]

According to a new post-hoc analysis presented today at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), people treated with Xultophy® had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (so-called 'bad cholesterol'), and significant weight changes in favour of Xultophy® compared to people treated with basal insulin (insulin glargine U100 or insulin degludec). A small but statistically significant increase in heart rate was also observed with Xultophy®.[1]

"People with type 2 diabetes have a higher risk of a heart attack or stroke compared to the general population, so reducing this risk as much as possible should be a central goal of treatment", said Professor Tina Vilsbøll, Steno Diabetes Center Copenhagen, Denmark & Center for Diabetes Research, Gentofte Hospital, Copenhagen, Denmark. "I am very pleased to see the beneficial effects on cardiovascular risk markers provided by Xultophy®."

CVD is the principal cause of death and disability among people with type 2 diabetes globally, with approximately two-thirds of deaths in people with diabetes attributable to CVD.[2] Therefore, treatments for type 2 diabetes should not only lower blood sugar levels but also decrease CV risk.[3]

"This added benefit of Xultophy® is certainly great news for the population at risk of developing cardiovascular disease on top of their existing type 2 diabetes", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "At Novo Nordisk we strive to develop innovative treatments, reinforcing our long-term commitment to defeat diabetes. Xultophy® is a key component of this commitment."

About the study

The CV risk markers data came from a new post-hoc analysis of two Xultophy® randomised-controlled clinical trials, comparing the efficacy and safety of Xultophy® against insulin degludec in DUAL II and against insulin glargine U100 in DUAL V, both with metformin for 26 weeks.[4],[5] These trials were conducted in people with type 2 diabetes not achieving glycaemic control (HbA1c 7.5-10.0% in DUAL II; 7.0-10.0% in DUAL V) on basal insulin (20-40 units in DUAL II; 20-50 units in DUAL V). The primary results from these trials have been reported previously.[4],[5]

About Xultophy®

Xultophy® is a once-daily single injection fixed-ratio combination of long-acting insulin degludec (Tresiba®) and the GLP-1 receptor agonist liraglutide (Victoza®) in one pen. It is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control. Xultophy® is given once daily by subcutaneous injection. Xultophy® can be administered at any time of the day with or without meals, preferably at the same time of the day.[6] On 18 September 2014, Xultophy® was granted marketing authorisation by the European Commission. On 21 November 2016, Xultophy® was approved by the FDA under the brand name Xultophy® 100/3.6.[6],[7]

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. For more information, visit http://novonordisk.com , Facebook, Twitter, LinkedIn, YouTube .

References

1. Vilsbøll T BT, Bode BW, et al. IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V. Abstract at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017.

2. Low Wang C, Hess C, Goldfine A. Clinical update: cardiovascular disease in diabetes mellitus. Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, managment of patients with stable ischemic heart disease. J Am Coll Cardiol. 2016;60:e44-e164.

3. Kurukulasuriya L, Sowers J. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol. 2010;9:1-13.

4. Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014:2926-2933.

5. Lingvay I, Harris S, Jaeckel E, et al. IDegLira was effective across a range of dysglycaemia and BMI categories in the DUAL V randomized trial. Diabetes Obes Metab. 2017. DOI: 10.1111/dom.13043.

6. EMA. Xultophy® Summary of Product Characteristics. Available at: http://ift.tt/2cnOzyc. Last accessed: September 2017.

7. Novo Nordisk. Novo Nordisk recieves US FDA approval for Xultophy® 100/3.6. Available at:http://ift.tt/2fS4NiQ. Last accessed: September 2017.

Further Information:

Media: Katrine Sperling +45-4442-6718 [email protected]

Åsa Josefsson +45-3079-7708 [email protected]

Investors: Peter Hugreffe Ankersen +45-3075-9085 [email protected]

Hanna Ögren +45-3079-8519 [email protected]

Anders Mikkelsen +45-3079-4461 [email protected]

Christina Jensen +45-3079-3009 [email protected]

Kasper Veje (US) +1-609-235-8567 [email protected]

Read this news on PR Newswire Asia website: Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

#Healthcare

0 notes

type2diabetestreatments-blog · 8 years ago

Text

13 Diabetes Products in the Pipeline

New Post has been published on http://type2diabetestreatment.net/diabetes-news/13-diabetes-products-in-the-pipeline/

13 Diabetes Products in the Pipeline

Welcome to the future of diabetes management

By Tracey Neithercott, Allison Tsai, and Kimberly Goad March 2017

Innovation is moving faster than ever, and that’s true in the diabetes world, too. Each year, new products are pushed out of the pipeline in the hopes of making diabetes management easier and more accurate. Here are some we eagerly await.

Stand-Alone CGM

There’s been talk about Medtronic’s latest combo continuous glucose monitor (CGM)–pump, but lost in all that chatter is that the company has set its sights on a device for people taking multiple daily injections, too. Enter the Guardian Connect, a stand-alone continuous glucose monitor (not connected to a pump). Every five minutes, the CGM will transmit a reading to a smart device (Apple first; Android later), where you can view data or send readings and reports to family, caregivers, or a health care provider. The device will connect with the Sugar IQ app, which uses IBM’s Watson supercomputer to mine the data and provide insight—say, your glucose trends low around 3 p.m. each day. Guardian Connect is currently under review by the Food and Drug Administration (FDA).

Artificial Pancreas

To reach its goal of a partial artificial pancreas—a system that will automatically deliver basal insulin and bolus correction doses—by the summer of 2018, Tandem Diabetes is teaming up with CGM manufacturer Dexcom for a three-part project. First comes the integration of Dexcom’s G5 sensor with Tandem’s T:slim X2 pump. FDA clearance is expected by midyear. After that: an X2 pump with CGM integration that tracks glucose trends, then stops insulin delivery before your glucose drops too low—estimated to release by the end of the year. But the big deal is a pump that does all of the above, plus uses CGM data to automatically deliver basal insulin and bolus correction doses when your glucose rises. You’d still need to enter carbs and bolus for meals. If all goes according to plan, that could be on the market by June 2018.

Smart Cap

Common Sensing’s Gocap can log doses from any disposable, prefilled insulin pen. Attach it to your pen and, using optical sensors, it will determine how much insulin you’ve delivered. Doses are displayed on the screen and automatically logged, making it easy for you to share with your provider and family. Other features include wireless communication with certain meters and an app that helps translate your dosing and blood glucose data so you can better manage your diabetes. Pilot clinical studies are underway, and the cap is expected to be available through certain insurance plans sometime this year.

Sensor Log

Another memory tool for insulin pens is in the early design stages. Insulog uses sensors to determine how much insulin you’ve taken—and when. The device snaps onto the side of an insulin pen and displays information on a digital screen. It also streams data via Bluetooth to a companion app.

Disposable CGM

Dexcom is teaming up with Verily (the life sciences division of Google’s parent company, Alphabet) to create a disposable continuous glucose monitoring system for people with type 2 diabetes. Over the course of its 14-day lifespan, a sensor would send your readings to a smartphone app so you can easily share with family or your health care provider. At launch, the above-skin portion of the sensor will be smaller than a quarter, but by 2020 the company hopes to have reduced it to the size of an M&M candy. An added bonus: The device won’t require finger-stick calibration. Dexcom sees the disposable CGM as a device people with type 2 could use as needed for greater insight into their glucose levels—say, with diet or exercise changes. The system is expected to release in 2018.

Insulin Pill

One of the elusive goals of insulin research is developing a pill you can take daily. There’s just one problem: Because insulin is a protein-based drug, the stomach digests it before it has time to do your blood glucose any good. Professor Mary McCourt, PhD, and her team at Niagara University are working on a solution. They theorize that by putting insulin into a container made of molecules the stomach won’t break down, they can create an insulin pill that’ll pass through the stomach. Their technology, named Cholestosome, uses naturally occurring lipid molecules—the building blocks of fats—to create cavities that can hold the insulin. Because of its makeup, Cholestosome can resist breakdown by stomach acid as it passes through the stomach. Once in the intestines, Cholestosome is absorbed, and insulin is released. The researchers are in the early stages of development, and more animal studies are ahead.

Implantable CGM

Not a fan of replacing your CGM sensor every week? In the future, you might go as long as three months between sensor changes. Senseonics’ system includes a 90-day, pill-sized sensor that’s inserted beneath the skin of the upper arm and a removable transmitter (a bit larger than traditional CGM transmitters) that rests just above, on top of the skin. Using fluorescent technology, the sensor monitors glucose, then wirelessly sends the data to the transmitter. That, in turn, sends data to a smartphone app. Sensor insertion and removal is done by a doctor during a short office visit. Within 24 hours, users can begin getting readings, and within 48 hours the insertion site will be fully healed. The CGM is currently available in Europe and was submitted to the FDA for premarket approval in late 2016. The goal: a U.S. launch by the end of this year or early 2018.

Tubeless Artificial Pancreas

Insulet is conducting clinical trials for its Omnipod Horizon partial artificial pancreas system that’ll run on its tubeless pump and with a CGM sensor—the company hopes to use Dexcom’s next-generation G6 version—and an Android-based handheld receiver to control functions. The system, which users will be able to customize using the handheld device, automatically controls basal insulin, though users will need to manually deliver mealtime boluses. Testing on the system has already begun, and in 2018 Insulet plans to conduct a pivotal trial, with a product release tentatively scheduled for 2019.

Patch Pump

In the pipeline for people with type 2: a lower-tech insulin delivery option from Becton, Dickinson, and Co. The disposable device delivers both basal and bolus insulin directly from a patch that’s worn on the skin for up to three days. A Bluetooth receiver wirelessly communicates with the device and relays information to a smartphone app. Look for it in 2018.

Retinopathy Mask

Long-term high blood glucose can deprive the retina of oxygen and cause growth of weak blood vessels that leak, all of which impairs vision. The current treatments for the condition, known as diabetic retinopathy: injectable drugs, laser therapy, and surgery. But in the future, you may be able to treat it while you sleep. PolyPhotonix’s Noctura 400 Sleep Mask emits low-level light through your eyelids during slumber, which the company claims reduces the amount of oxygen the eyes need during the night and minimizes the growth of weakened vessels. (More research is needed to determine whether this technology can effectively treat diabetic retinopathy.) Right now, it’s available only in the United Kingdom, but PolyPhotonix has submitted the product for FDA review.

Coming Soon

These products are just around the corner

Medtronic MiniMed 670G

This is what you’ve been waiting for: a partial artificial pancreas, a hybrid closed-loop insulin pump that automatically adjusts your basal insulin delivery based on your glucose level. (You still need to manually bolus for meals, though.) The system, which includes a more accurate CGM sensor, has received FDA approval and is set to launch this spring.

Xultophy

Both insulin degludec (Tresiba) and liraglutide (Victoza) have been out on the market for years. Now Novo Nordisk is combining the two in a mix that will treat type 2 diabetes in a new way. The FDA has approved the injectable drug, Xultophy, and it’s set to release by midyear.

OneTouch Vibe Plus

The FDA has cleared Animas’s latest insulin pump, which is integrated with Dexcom’s G5 Mobile CGM system. Download Dexcom’s app onto a smartphone to get glucose readings, trends, and to program the pump to deliver insulin. Friends, caregivers, and health care providers using another app can see your real-time glucose data. No word yet on the product’s specific launch date.

Type 2 Diabetes Treatment Type 2 Diabetes Diet Diabetes Destroyer Reviews Original Article

0 notes